Platform: SCF Biotech System Therapeutics

Technology Class: Lymph Node–Targeted Nanocarrier Delivery System

Primary Application: HIV Reservoir Penetration and Microenvironment Reconstruction

Reaching the Hidden Reservoirs of Disease

Many of the most persistent diseases—including chronic viral infections—are sustained by biological compartments that conventional therapeutics cannot effectively reach.

In HIV infection, the virus persists within immune sanctuary sites such as lymph nodes, gut-associated lymphoid tissue, and specialized immune cell populations. These environments are protected by structural barriers including extracellular matrix fibrosis, altered lymphatic flow, and restricted immune access.

The SCF Lymphotropic Nanocarrier System™ was engineered to overcome these barriers by delivering therapeutic payloads directly into the microenvironments where viral persistence is maintained.

A Delivery Platform Built for Immune System Architecture

Traditional drug delivery methods rely primarily on systemic circulation to distribute therapeutics. However, this approach often results in insufficient drug penetration within lymphatic tissues and immune reservoirs.

The SCF nanocarrier platform introduces a lymphotropic delivery architecture designed specifically for targeting immune system structures.

Key design capabilities include:

• selective homing to lymphatic tissues
• penetration of fibrotic extracellular matrix structures
• controlled multi-agent therapeutic release
• compatibility with system-level therapeutic stacks.

These capabilities enable drugs to reach anatomical compartments that are traditionally inaccessible to standard formulations.

Engineering for Lymphatic Targeting

The SCF nanocarrier platform is built around a lipid–polymer hybrid nanoparticle architecture optimized for lymphatic uptake.

Particles are engineered within a precisely controlled nanoscale range that enables efficient transport through lymphatic drainage pathways and retention within lymph node structures.

Surface ligands guide the nanocarriers to immune microenvironments using biological homing signals that interact with lymphatic trafficking pathways.

These targeting features enable the system to selectively accumulate within immune compartments where persistent pathogens and immune dysfunction reside.

Penetrating Fibrotic Immune Microenvironments

Chronic HIV infection frequently produces fibrosis within lymph nodes, where collagen accumulation disrupts immune architecture and shields viral reservoirs from therapeutic access.

The SCF nanocarrier system incorporates ECM-adaptive engineering features designed to penetrate these fibrotic environments without destabilizing tissue structure.

Key capabilities include:

• reversible collagen-binding interfaces
• matrix metalloproteinase–responsive surface domains
• adaptive integrin-interaction profiles.

These design elements allow therapeutic payloads to navigate dense extracellular matrices and access immune cell niches that are otherwise protected from drug exposure.

Multi-Payload Therapeutic Delivery

The nanocarrier platform supports layered payload architecture, enabling simultaneous delivery of multiple therapeutic agents within a single nanoparticle system.

This design allows coordinated delivery of:

• antiretroviral compounds
• anti-fibrotic microenvironment modulators
• latency-targeting agents.

By delivering complementary therapeutic components in a synchronized manner, the system supports the SCF Preventative–Curative–Restorative (PCR) therapeutic sequence.

Targeting the Architecture of Viral Persistence

Persistent viral reservoirs are sustained through a combination of structural protection, immune evasion, and metabolic suppression.

Within lymphatic tissues, fibrosis and altered immune signaling create niches where infected cells remain shielded from both drug exposure and immune surveillance.

The SCF Lymphotropic Nanocarrier System addresses this challenge by increasing therapeutic concentration within lymph node T-cell zones and improving cytotoxic immune access to infected cells.

This approach directly targets the biological architecture that maintains viral persistence.

Designed for Precision Pharmacology

The nanocarrier system incorporates several engineering parameters designed to optimize therapeutic performance.

These include:

• controlled particle size for lymphatic uptake
• neutral surface charge to maintain immune compatibility
• tissue-biased biodistribution profiles
• controlled release kinetics aligned with immune rhythms.

Together, these features create a delivery system capable of transporting therapeutics into immune microenvironments while maintaining systemic safety.

Preclinical Validation and Translational Development

The SCF Lymphotropic Nanocarrier System is currently advancing through a structured translational development pathway.

Preclinical studies focus on:

• biodistribution mapping using fluorescence and radiotracing
• extracellular matrix penetration modeling
• lymph node drug concentration measurements
• reservoir quantification using viral DNA assays.

These studies establish the foundation for advancing the nanocarrier system toward IND-enabling chemistry, manufacturing, and controls (CMC) development.

Enabling the Next Generation of System Therapeutics

The SCF Lymphotropic Nanocarrier System serves as the delivery backbone for system-level therapeutic strategies, enabling advanced therapies to reach the biological compartments where disease persists.

By combining lymphatic targeting, ECM-compatible engineering, and multi-agent delivery capabilities, the platform opens new possibilities for treating diseases sustained by protected tissue microenvironments.

In this model, drug delivery is no longer limited to systemic circulation—it becomes a precision tool for accessing the structural architecture of disease.